Concepedia

Author

Jian Fang

Peking UniversityORCID

Also Known As

Bao-feng Zhang, Fang J, Fang, Jian, Hanwen Zhang, J Fang, J. Fang, Jian Fang, Jian Hong Fang, Jianbang Fang, Jiaxu Fang

243

Publications

6.2K

Citations

35

H-Index

68

Concepts

All Affiliations

Peking UniversityPeking University Cancer HospitalZhejiang Cancer HospitalHarbin Medical UniversityHunan Cancer Hospital
JF

About

Jian Fang is an author at Peking University specializing in medicine, cancer therapeutics, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

24

38

2.7K

2

Health Sciences

9

9

1.1K

3

Engineering

1

1

153

4

Natural Sciences

1

1

53

5

Biochemistry

1

1

53

Jian Fang

×

80

Publications

5.1K

Citations

33

H-Index

YearCitations

Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial

Caicun Zhou, Gongyan Chen, Yunchao Huang,

The Lancet Respiratory Medicine

2020

488

Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)

Yunpeng Yang, Zhehai Wang, Jian Fang,

Journal of Thoracic Oncology

2020

376

Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial

Shengxiang Ren, Jianhua Chen, Xingxiang Xu,

Journal of Thoracic Oncology

2021

293

AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With <i>EGFR</i> Exon 19 Deletion or L858R Mutations

Shun Lü, Xiaorong Dong, Hong Jian,

Journal of Clinical Oncology

2022

253

Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial

Shun Lü, Lin Wu, Hong Jian,

The Lancet Oncology

2022

227

Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications

Natalia Lapteva, April Durett, Jiali Sun,

Cytotherapy

2012

202

Pyrotinib in <i>HER2</i>-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study

Caicun Zhou, Xingya Li, Qiming Wang,

Journal of Clinical Oncology

2020

197

Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial

Shun Lü, Lin Wu, Hong Jian,

The Lancet Respiratory Medicine

2023

181

Identification of heavy metal sources in the reclaimed farmland soils of the pearl river estuary in China using a multivariate geostatistical approach

Yang Gu, Qu Sheng Li, Jian Fang,

Ecotoxicology and Environmental Safety

2014

153

Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial

James Chih‐Hsin Yang, D. Ross Camidge, Cheng‐Ta Yang,

Journal of Thoracic Oncology

2020

149

Page 1